Vor Biopharma Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Vor Biopharma Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Debt Due Cover Ratio: Operating cash was negative last year, while some debt falls due within a year. Lower than 97% of Healthcare companies in United States.
- Shareholder Slice Ratio: Share count rose 1,073% in 3 years, so each share's slice of the company became smaller. Bigger rise in share count than 90% of Healthcare companies in United States.
- Steadiness Ratio: Sales grew in 0 of the last 3 years; profit grew in 1 of 3. Less steady than 86% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
-153.0×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 86% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 1/3Sales grew in 0 of the last 3 years; profit grew in 1 of 3.
Less steady than 86% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-509.7×Operating cash was negative last year, while some debt falls due within a year.
Lower than 97% of Healthcare companies in United States.
Cash Cushion Ratio
+40%Cash, after subtracting all debt, equals 40% of its market value (net cash).
Higher than 74% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (8)
Vor Biopharma Inc. owes $1.42 for every $1 it owns. Vor Biopharma Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
0.1Investors pay $0.1 for every $1 of Vor Biopharma Inc.'s yearly profit, lower than 96% of Healthcare companies in United States.
P/B ratio
-5.40Vor Biopharma Inc.'s book value is negative (it owes more than it owns), so P/B is not meaningful.
Market cap
$1.1 BThe total market value of all of Vor Biopharma Inc.'s shares at today's price (share price × number of shares), larger than 65% of Healthcare companies in United States. PosiCap size class: Meso Cap.
Net worth (book value)
NegativeVor Biopharma Inc.'s net worth is negative ($200 M below zero, balance sheet 30 Jun 2026): it owes more than it owns, so book value per share and P/B are not meaningful.
Owes vs Owns
1.42×Vor Biopharma Inc. owes $1.42 for every $1 it owns, so it owes more than it owns, higher than 93% of Healthcare companies in United States.
Dividend yield
NoneVor Biopharma Inc. does not currently pay a dividend.
Profit growth
LossVor Biopharma Inc. made a loss in each of the last two years.
Cash vs debt
Net cashVor Biopharma Inc. held $452 M more cash than debt (net cash) at Dec 2025.
Questions
What is Vor Biopharma Inc.'s P/E ratio?
Investors pay $0.1 for every $1 of Vor Biopharma Inc.'s yearly profit, lower than 96% of Healthcare companies in United States.
How much does Vor Biopharma Inc. owe compared with what it owns?
Vor Biopharma Inc. owes $1.42 for every $1 it owns, so it owes more than it owns, higher than 93% of Healthcare companies in United States.
Does Vor Biopharma Inc. pay a dividend?
No. Vor Biopharma Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.